Van ECK Associates Corp Cuts Stake in CVS Health Corporation $CVS

Van ECK Associates Corp cut its position in CVS Health Corporation (NYSE:CVS - Free Report) by 85.5% in the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 226,203 shares of the pharmacy operator's stock after selling 1,334,536 shares during the period. Van ECK Associates Corp's holdings in CVS Health were worth $23,401,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in CVS. Kilter Group LLC bought a new position in CVS Health in the 2nd quarter valued at approximately $27,000. Beaird Harris Wealth Management LLC increased its holdings in shares of CVS Health by 201.0% in the 2nd quarter. Beaird Harris Wealth Management LLC now owns 292 shares of the pharmacy operator's stock worth $30,000 after purchasing an additional 195 shares in the last quarter. J.Safra Asset Management Corp purchased a new position in shares of CVS Health in the second quarter worth $30,000. Dunhill Financial LLC bought a new position in shares of CVS Health during the second quarter valued at $32,000. Finally, Swiss RE Ltd. purchased a new stake in shares of CVS Health during the fourth quarter valued at $26,000. Hedge funds and other institutional investors own 80.66% of the company's stock.

CVS Health Trading Up 0.1%

NYSE:CVS opened at $93.15 on Monday. CVS Health Corporation has a one year low of $69.51 and a one year high of $110.68. The business has a fifty day moving average price of $101.42 and a 200-day moving average price of $89.55. The firm has a market capitalization of $119.14 billion, a price-to-earnings ratio of 24.64, a price-to-earnings-growth ratio of 0.91 and a beta of 0.61. The company has a debt-to-equity ratio of 0.74, a current ratio of 0.87 and a quick ratio of 0.66.

CVS Health (NYSE:CVS - Get Free Report) last released its quarterly earnings results on Wednesday, August 5th. The pharmacy operator reported $2.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.87 by $0.71. The business had revenue of $106.10 billion during the quarter, compared to analyst estimates of $100.03 billion. CVS Health had a return on equity of 13.12% and a net margin of 1.18%.CVS Health's revenue for the quarter was up 7.3% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.81 earnings per share. CVS Health has set its FY 2026 guidance at 7.900-8.100 EPS. Sell-side analysts forecast that CVS Health Corporation will post 8.02 EPS for the current year.

CVS Health Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, August 3rd. Investors of record on Thursday, July 23rd were paid a dividend of $0.665 per share. The ex-dividend date was Thursday, July 23rd. This represents a $2.66 dividend on an annualized basis and a dividend yield of 2.9%. CVS Health's payout ratio is 70.37%.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on CVS. HSBC restated a "hold" rating and set a $103.00 price objective on shares of CVS Health in a research report on Monday, July 6th. Bank of America raised their price target on CVS Health from $100.00 to $110.00 and gave the stock a "buy" rating in a research note on Monday, June 22nd. Deutsche Bank Aktiengesellschaft upped their price objective on CVS Health from $88.00 to $92.00 and gave the company a "buy" rating in a research report on Thursday, May 7th. UBS Group boosted their price target on CVS Health from $122.00 to $126.00 and gave the company a "buy" rating in a research note on Thursday, August 6th. Finally, Argus increased their price objective on shares of CVS Health from $104.00 to $114.00 and gave the stock a "buy" rating in a research note on Wednesday, August 19th. Twenty-two analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $107.17.

More CVS Health News

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: Pharmacy momentum supports the turnaround case. Rising prescription volumes, gains associated with Rite Aid and improving pharmacy profitability could provide support for CVS’s second-half outlook. This adds to the company’s recent earnings momentum, including revenue growth and an earnings beat in its latest reported quarter. How CVS' Pharmacy and Consumer Wellness Is Positioned for H2 2026
• Positive Sentiment: Updated flu vaccines are now available nationwide. CVS Pharmacy and MinuteClinic are offering the 2026–2027 vaccines, while expanded testing and treatment services may increase seasonal customer traffic. A company survey found that more than 60% of consumers are likely to get a flu shot, though the earnings effect is likely to be seasonal and modest. CVS Pharmacy and MinuteClinic Now Offering Updated Flu Vaccines Nationwide
• Positive Sentiment: Value-focused coverage is reinforcing rebound expectations. Zacks characterizes CVS as a potential long-term value stock, while Trefis notes that the company’s historical drawdowns have often eventually recovered. These are sentiment and valuation arguments rather than new financial guidance, but they may attract investors seeking a healthcare turnaround at a relatively reasonable valuation. Why CVS Health Is a Top Value Stock for the Long-Term
• Neutral Sentiment: ACA insurer exits create both opportunity and uncertainty. Cigna, Molina and other carriers are leaving Obamacare exchanges in 2027. The disruption could create enrollment opportunities for Aetna, CVS’s insurance business, but also highlights regulatory, pricing and membership risks across the sector. All the Insurers Exiting ACA Obamacare Exchanges for 2027
• Negative Sentiment: Political pressure on vertically integrated healthcare companies remains a risk. Mark Cuban’s support for breaking up “big medicine” adds to scrutiny of insurers, pharmacy benefit managers and large healthcare platforms. No specific policy action against CVS was announced, but potential structural or regulatory changes could weigh on sentiment. Mark Cuban Backs Plan to Break Up Big Medicine

CVS Health Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source